On Wednesday, 1 May 2019, The Therapeutic Goods Administration (TGA) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10-17 years old with relapsing forms of multiple sclerosis.
The registration makes Gilenya the first licenced disease-modifying treatment for children and adolescents in Australia.
The decision was announced by Novartis after a global study proved its positive effects in reducing relapses with fewer side effects.
Up until now children have been prescribed adult medication, leaving them with uncomfortable side effects.
View the treatment sheet.